Literature DB >> 1901240

Gonadal protection and fecundity rates in cyclophosphamide-treated rats.

F J Montz1, A J Wolff, J C Gambone.   

Abstract

Premature ovarian failure and reduced fecundity are well-documented consequences of cytotoxic chemotherapy used to treat patients with malignant diseases. To investigate the ability of different hormonal agents to block the effects of cyclophosphamide (CTX) on reproductive function, sexually mature female Long-Evans rats were studied. Model development demonstrated that CTX, 6 mg/kg/day, 5 days/week for 3 weeks, was successful at inducing acyclicity and significantly reducing fertility and fecundity, with acceptable mortality, when compared to higher/lower dosages. Utilizing this model, animals were treated with CTX in combination with an inert vehicle, Lupron, 80 micrograms/kg every 24 h, Lupron, 40 micrograms/kg every 12 h, or s.c. progesterone capsules obtaining serum progesterone levels of 20-30 ng/ml. We concluded that progesterone was able to protect the gonad from the negative effects of CTX, maintaining fertility and fecundity rates not significantly different from those of untreated control animals. Lupron given every 12 h had a similar effect on fertility, but failed to protect fecundity (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901240

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  A Combination of a GnRH Antagonist and Agonist for Fertility Preservation in an Adolescent Female Murine Model.

Authors:  Jennifer Flora Knudtson; Marlen Tellez Santos; Courtney M Failor; Peter A Binkley; Jacob P Venesky; Rajeshwar R Tekmal; Randal D Robinson; Robert S Schenken
Journal:  Reprod Sci       Date:  2016-12-14       Impact factor: 3.060

2.  Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide.

Authors:  Claudia N C D Lemos; Fernando M Reis; Guilherme N Pena; Laila C Silveira; Aroldo F Camargos
Journal:  Reprod Biol Endocrinol       Date:  2010-05-18       Impact factor: 5.211

Review 3.  Preservation of fertility in women undergoing chemotherapy: current approach and future prospects.

Authors:  R Abir; B Fisch; A Raz; S Nitke; Z Ben-Rafael
Journal:  J Assist Reprod Genet       Date:  1998-09       Impact factor: 3.412

4.  Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.

Authors:  E M McDermott; R J Powell
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

5.  Multiple approaches for individualized fertility protective therapy in cancer patients.

Authors:  I Demeestere; F Moffa; F Peccatori; C Poirot; E Shalom-Paz
Journal:  Obstet Gynecol Int       Date:  2011-12-29

6.  Loss of PUMA protects the ovarian reserve during DNA-damaging chemotherapy and preserves fertility.

Authors:  Quynh-Nhu Nguyen; Nadeen Zerafa; Seng H Liew; F Hamish Morgan; Andreas Strasser; Clare L Scott; Jock K Findlay; Martha Hickey; Karla J Hutt
Journal:  Cell Death Dis       Date:  2018-05-23       Impact factor: 8.469

Review 7.  Preservation of Fertility in Female Cancer Patients Desiring Future Child Bearing; What is Available and What can be Offered.

Authors:  Nader Husseinzadeh; Holleh D Husseinzadeh
Journal:  World J Oncol       Date:  2013-03-06

8.  Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model.

Authors:  Florence Horicks; Géraldine Van Den Steen; Sarah Houben; Yvon Englert; Isabelle Demeestere
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.